

Richard F Ambinder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9109257/publications.pdf>

Version: 2024-02-01

309
papers

17,225
citations

12330

69
h-index

17592

121
g-index

313
all docs

313
docs citations

313
times ranked

13849
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 641-650.	2.0	1,525
2	Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. <i>Cancer Research</i> , 2008, 68, 190-197.	0.9	495
3	Acyclovir Halts Progression of Herpes Zoster in Immunocompromised Patients. <i>New England Journal of Medicine</i> , 1983, 308, 1448-1453.	27.0	437
4	Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-Hydroperoxycyclophosphamide. <i>New England Journal of Medicine</i> , 1986, 315, 141-147.	27.0	431
5	Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data. <i>International Journal of Cancer</i> , 1997, 70, 375-382.	5.1	424
6	Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. <i>Blood</i> , 2005, 106, 1538-1543.	1.4	390
7	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. <i>Blood</i> , 2010, 115, 3224-3230.	1.4	346
8	Hodgkin lymphoma: A review and update on recent progress. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 116-132.	329.8	315
9	Detection of ebv gene expression in reed-sternberg cells of Hodgkin's disease. <i>International Journal of Cancer</i> , 1990, 46, 801-804.	5.1	272
10	Chemotherapy for Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma in Combination With Highly Active Antiretroviral Therapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 2171-2178.	1.6	264
11	Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 482-489.	2.0	260
12	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. <i>Blood</i> , 2015, 125, 3024-3031.	1.4	259
13	Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2010, 115, 3008-3016.	1.4	254
14	Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1279-1287.	2.0	251
15	The Stress-Responsive Gene <i>CADD45G</i> Is a Functional Tumor Suppressor, with Its Response to Environmental Stresses Frequently Disrupted Epigenetically in Multiple Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 6442-6449.	7.0	220
16	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. <i>Journal of Clinical Oncology</i> , 2015, 33, 3152-3161.	1.6	215
17	A Survey of Epstein-Barr Virus DNA in Lymphoid Tissue: Frequent Detection in Hodgkin's Disease. <i>American Journal of Clinical Pathology</i> , 1989, 91, 1-5.	0.7	206
18	Comparison of Genetic Variability at Multiple Loci across the Genomes of the Major Subtypes of Kaposi's Sarcoma-Associated Herpesvirus Reveals Evidence for Recombination and for Two Distinct Types of Open Reading Frame K15 Alleles at the Right-Hand End. <i>Journal of Virology</i> , 1999, 73, 6646-6660.	3.4	189

#	ARTICLE	IF	CITATIONS
19	Spindle Cell Conversion by Kaposi's Sarcoma-Associated Herpesvirus: Formation of Colonies and Plaques with Mixed Lytic and Latent Gene Expression in Infected Primary Dermal Microvascular Endothelial Cell Cultures. <i>Journal of Virology</i> , 2001, 75, 5614-5626.	3.4	178
20	Epstein-Barr Virus (EBV) in Endemic Burkitt's Lymphoma: Molecular Analysis of Primary Tumor Tissue. <i>Blood</i> , 1998, 91, 1373-1381.	1.4	169
21	Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. <i>Blood</i> , 2000, 96, 4055-4063.	1.4	167
22	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <i>Blood</i> , 2014, 124, 3817-3827.	1.4	165
23	Long-Term Results of Blood and Marrow Transplantation for Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 4314-4321.	1.6	163
24	Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1662-1668.	1.6	161
25	Circulating clonotypic B cells in classic Hodgkin lymphoma. <i>Blood</i> , 2009, 113, 5920-5926.	1.4	159
26	The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. <i>Blood</i> , 2016, 127, 2007-2017.	1.4	158
27	Epstein-Barr Virus As a Marker of Survival After Hodgkin's Lymphoma: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 7604-7613.	1.6	155
28	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. <i>Haematologica</i> , 2017, 102, 391-400.	3.5	152
29	Conserved Herpesvirus Kinases Target the DNA Damage Response Pathway and TIP60 Histone Acetyltransferase to Promote Virus Replication. <i>Cell Host and Microbe</i> , 2011, 10, 390-400.	11.0	148
30	A New Primary Effusion Lymphoma-Derived Cell Line Yields a Highly Infectious Kaposi's Sarcoma Herpesvirus-Containing Supernatant. <i>Journal of Virology</i> , 2000, 74, 10187-10193.	3.4	147
31	Guidelines for Interpreting EBER In Situ Hybridization and LMP1 Immunohistochemical Tests for Detecting Epstein-Barr Virus in Hodgkin Lymphoma. <i>American Journal of Clinical Pathology</i> , 2002, 117, 259-267.	0.7	138
32	Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma. <i>Cancer</i> , 2010, 116, 3969-3977.	4.1	138
33	Use of antineoplastic agents in patients with cancer who have HIV/AIDS. <i>Lancet Oncology</i> , The, 2011, 12, 905-912.	10.7	137
34	Patterns of Gene Expression and a Transactivation Function Exhibited by the vGCR (ORF74) Chemokine Receptor Protein of Kaposi's Sarcoma-Associated Herpesvirus. <i>Journal of Virology</i> , 2002, 76, 3421-3439.	3.4	135
35	Linkage between STAT Regulation and Epstein-Barr Virus Gene Expression in Tumors. <i>Journal of Virology</i> , 2001, 75, 2929-2937.	3.4	132
36	Gammaherpesviruses and c-Myc and Runx2 Oncogenesis. <i>American Journal of Pathology</i> , 2000, 156, 1-3.	3.8	131

#	ARTICLE	IF	CITATIONS
37	Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 1373-1381.	1.6	129
38	B-Cell Stimulatory Cytokines and Markers of Immune Activation Are Elevated Several Years Prior to the Diagnosis of Systemic AIDS-Associated Non-Hodgkin B-Cell Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1303-1314.	2.5	125
39	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.	1.4	117
40	Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494). <i>Journal of Clinical Oncology</i> , 2004, 22, 1491-1500.	1.6	114
41	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. <i>Lancet Haematology</i> , 2019, 6, e183-e193.	4.6	111
42	High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. <i>Blood</i> , 2010, 115, 2136-2141.	1.4	107
43	Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. <i>Science Translational Medicine</i> , 2015, 7, 288ra78.	12.4	104
44	Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1514-1517.	2.0	103
45	HIV-1 DNA Is Detected in Bone Marrow Populations Containing CD4+ T Cells but Is not Found in Purified CD34+ Hematopoietic Progenitor Cells in Most Patients on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2012, 205, 1014-1018.	4.0	102
46	Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease. <i>American Journal of Pathology</i> , 1999, 155, 619-625.	3.8	100
47	Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 628-632.	2.0	98
48	Induction of Epstein-Barr Virus Kinases To Sensitize Tumor Cells to Nucleoside Analogues. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2082-2091.	3.2	97
49	Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. <i>Cancer</i> , 2003, 98, 300-309.	4.1	96
50	Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 755-781.	4.9	94
51	Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens. <i>Blood</i> , 2000, 95, 241-248.	1.4	92
52	Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. <i>Blood Advances</i> , 2020, 4, 1770-1779.	5.2	92
53	Human Herpesvirus 8-Encoded Thymidine Kinase and Phosphotransferase Homologues Confer Sensitivity to Ganciclovir. <i>Journal of Virology</i> , 1999, 73, 4786-4793.	3.4	91
54	Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 589-597.	4.9	90

#	ARTICLE	IF	CITATIONS
55	Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. <i>Scientific Reports</i> , 2016, 6, 26591.	3.3	90
56	National Marrow Donor Programâ€“Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	1.6	90
57	Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 602-606.	2.0	87
58	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , 2020, 7, e660-e670.	4.6	86
59	Epstein-Barr Virus Is Infrequently Identified in Non-Hodgkinâ€™s Lymphomas Associated with Hodgkinâ€™s Disease. <i>American Journal of Surgical Pathology</i> , 1994, 18, 48-61.	3.7	85
60	Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. <i>Nature Medicine</i> , 2008, 14, 1118-1122.	30.7	85
61	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2017, 1, 288-292.	5.2	84
62	DNA methylation and the Epsteinâ€“Barr virus. <i>Seminars in Cancer Biology</i> , 1999, 9, 369-375.	9.6	82
63	AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. <i>Blood</i> , 2015, 126, 160-166.	1.4	82
64	Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 608-638.	4.9	81
65	Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. <i>Molecular Immunology</i> , 2007, 44, 934-942.	2.2	80
66	A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 6241-6249.	7.0	80
67	Absence of Epstein-Barr virus EBER-1 transcripts in an epidemiologically diverse group of breast cancers. , 1998, 75, 555-558.		77
68	Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1797-1803.	1.6	75
69	Single-cell transcriptional landscapes reveal HIV-1â€“driven aberrant host gene transcription as a potential therapeutic target. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	75
70	Expression of Epstein-Barr Virus BamHI-A Rightward Transcripts in Latently Infected B Cells From Peripheral Blood. <i>Blood</i> , 1999, 93, 3026-3032.	1.4	74
71	Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. <i>Blood</i> , 2016, 128, 1050-1058.	1.4	74
72	Bortezomib induction of C/EBPâ€™2 mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. <i>Blood</i> , 2011, 117, 6297-6303.	1.4	72

#	ARTICLE	IF	CITATIONS
73	EBV-Related Lymphomas: New Approaches to Treatment. <i>Current Treatment Options in Oncology</i> , 2013, 14, 224-236.	3.0	70
74	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. <i>Blood</i> , 2017, 129, 1389-1393.	1.4	69
75	The Epstein-Barr Virus Major Latent Promoter Qp Is Constitutively Active, Hypomethylated, and Methylation Sensitive. <i>Journal of Virology</i> , 1998, 72, 7075-7083.	3.4	69
76	Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4129-4132.	1.4	67
77	Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 242-248.	2.0	64
78	Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 986-1017.	4.9	64
79	Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. <i>Journal of Clinical Investigation</i> , 2017, 127, 651-656.	8.2	64
80	Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. <i>Oncogene</i> , 2004, 23, 1326-1331.	5.9	63
81	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 325-332.	2.0	61
82	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1099-1102.	2.0	61
83	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 343-352.	2.0	61
84	IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients. <i>Oncotarget</i> , 2011, 2, 178-185.	1.8	61
85	Rapid in situ hybridization for the diagnosis of latent Epstein-Barr virus infection. <i>Molecular and Cellular Probes</i> , 1993, 7, 105-109.	2.1	60
86	Methylation of the Epstein-Barr Virus Genome in Normal Lymphocytes. <i>Blood</i> , 1997, 90, 4480-4484.	1.4	60
87	Epstein-barr virus detection in nasopharyngeal tissues of patients with suspected nasopharyngeal carcinoma. <i>Cancer</i> , 1998, 82, 1449-1453.	4.1	59
88	Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations. <i>International Journal of Cancer</i> , 2008, 123, 1499-1507.	5.1	57
89	Serum Levels of Cytokines and Biomarkers for Inflammation and Immune Activation, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 343-349.	2.5	57
90	PCR Detection of Adenovirus in a Bone Marrow Transplant Recipient: Hemorrhagic Cystitis as a Presenting Manifestation of Disseminated Disease. <i>Journal of Clinical Microbiology</i> , 1999, 37, 686-689.	3.9	57

#	ARTICLE	IF	CITATIONS
91	Graft-versus-Host Reactions and the Effectiveness of Donor Lymphocyte Infusions. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 414-421.	2.0	56
92	A Protein Array Screen for Kaposi's Sarcoma-Associated Herpesvirus LANA Interactors Links LANA to TIP60, PP2A Activity, and Telomere Shortening. <i>Journal of Virology</i> , 2012, 86, 5179-5191.	3.4	56
93	Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women. <i>Cancer</i> , 2001, 91, 1579-1587.	4.1	55
94	Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab. <i>Clinical Cancer Research</i> , 2007, 13, 2392-2399.	7.0	55
95	Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. <i>Oncotarget</i> , 2015, 6, 33849-33866.	1.8	55
96	Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2431-2437.	2.0	54
97	Virus-Associated Tumor Imaging by Induction of Viral Gene Expression. <i>Clinical Cancer Research</i> , 2007, 13, 1453-1458.	7.0	52
98	Frequent epigenetic silencing of <i>protocadherin 10</i> by methylation in multiple haematologic malignancies. <i>British Journal of Haematology</i> , 2007, 136, 829-832.	2.5	52
99	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. <i>Blood Advances</i> , 2020, 4, 3913-3925.	5.2	52
100	Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. <i>Current Opinion in Oncology</i> , 2013, 25, 495-502.	2.4	50
101	Serum Levels of the Chemokine CXCL13, Genetic Variation in <i>CXCL13</i> and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 295-307.	2.5	49
102	Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2018, 2, 2226-2229.	5.2	47
103	<i>t(11;18)(q21;q21)</i> is a recurrent chromosome abnormality in small lymphocytic lymphoma. <i>Genes Chromosomes and Cancer</i> , 1992, 4, 153-157.	2.8	45
104	NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 245-254.	4.9	45
105	Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin's Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 965-972.	2.0	44
106	Oligonucleotides for polymerase chain reaction amplification and hybridization detection of Epstein-Barr virus DNA in clinical specimens. <i>Molecular and Cellular Probes</i> , 1990, 4, 397-407.	2.1	43
107	AIDS primary central nervous system lymphoma. <i>Current Opinion in Oncology</i> , 1996, 8, 373-376.	2.4	43
108	Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β -catenin and AKT signaling but frequently methylated in common carcinomas. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 2179-2192.	5.4	43

#	ARTICLE	IF	CITATIONS
109	Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1887-1894.	2.0	42
110	Small Capsid Protein pORF65 Is Essential for Assembly of Kaposi's Sarcoma-Associated Herpesvirus Capsids. <i>Journal of Virology</i> , 2008, 82, 7201-7211.	3.4	41
111	Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1020-1058.	4.9	40
112	Human T Cell Leukemia Virus Reactivation with Progression of Adult T-Cell Leukemia-Lymphoma. <i>PLoS ONE</i> , 2009, 4, e4420.	2.5	40
113	Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). <i>Blood</i> , 2020, 136, 1284-1297.	1.4	39
114	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1128-1135.	2.0	38
115	Hodgkin Lymphoma, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 554-586.	4.9	37
116	Localized Herpes Simplex Lymphadenitis. <i>American Journal of Clinical Pathology</i> , 1986, 86, 444-448.	0.7	36
117	Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. <i>Blood Advances</i> , 2017, 1, 1324-1334.	5.2	36
118	AIDS-Related Kaposi Sarcoma, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 171-189.	4.9	35
119	NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 322-334.	4.9	35
120	Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 536-541.	2.0	34
121	Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). <i>Blood</i> , 2016, 128, 1106-1106.	1.4	34
122	Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas. <i>Blood</i> , 2004, 103, 743-746.	1.4	33
123	Comparison of Humoral Immune Responses to Epstein-Barr Virus and Kaposi's Sarcoma-Associated Herpesvirus Using a Viral Proteome Microarray. <i>Journal of Infectious Diseases</i> , 2011, 204, 1683-1691.	4.0	33
124	Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas. <i>Theranostics</i> , 2018, 8, 61-77.	10.0	33
125	HHV-8-positive and EBV-positive Intravascular Lymphoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 426-432.	3.7	32
126	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2056-2064.	2.0	32

#	ARTICLE	IF	CITATIONS
127	Feasibility of Cellular Adoptive Immunotherapy for Epstein-Barr Virus-Associated Lymphomas Using Haploidentical Donors. <i>Stem Cells and Development</i> , 1998, 7, 257-261.	1.0	31
128	Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 312-319.	2.0	31
129	Smoking and Hodgkin Lymphoma Risk in Women United States. <i>Cancer Causes and Control</i> , 2004, 15, 387-397.	1.8	30
130	Cancer biomarkers in HIV patients. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 531-537.	3.8	30
131	Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. <i>Journal of Medical Virology</i> , 2002, 68, 370-377.	5.0	29
132	Infectious, autoimmune and allergic diseases and risk of Hodgkin lymphoma in children and adolescents: A Children's Oncology Group study. <i>International Journal of Cancer</i> , 2014, 135, 1454-1469.	5.1	29
133	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1022-1028.	2.0	29
134	Tâ€cell receptor sequencing demonstrates persistence of virusâ€specific T cells after antiviral immunotherapy. <i>British Journal of Haematology</i> , 2019, 187, 206-218.	2.5	29
135	Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkinâ€™s lymphoma. , 2021, 9, e002097.		28
136	Exposure to childhood infections and risk of Epsteinâ€Barr virusâ€defined Hodgkin's lymphoma in women. <i>International Journal of Cancer</i> , 2005, 115, 599-605.	5.1	27
137	Tumor-Specific Methylation of the 8p22 Tumor Suppressor Gene DLC1 is an Epigenetic Biomarker for Hodgkin, Nasal NK/T-Cell and Other Types of Lymphomas. <i>Epigenetics</i> , 2007, 2, 15-21.	2.7	27
138	Nelfinavir Inhibits Maturation and Export of Herpes Simplex Virus 1. <i>Journal of Virology</i> , 2014, 88, 5455-5461.	3.4	27
139	Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. <i>Blood Advances</i> , 2017, 1, 681-684.	5.2	27
140	As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2018, 67, 251-260.	5.8	27
141	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2160-2166.	2.0	27
142	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2115-2122.	2.0	26
143	De Novo DNA Methyltransferase DNMT3b Interacts with NEDD8-modified Proteins. <i>Journal of Biological Chemistry</i> , 2010, 285, 36377-36386.	3.4	25
144	Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1679-1688.	2.0	25

#	ARTICLE	IF	CITATIONS
145	Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). <i>Blood</i> , 2015, 126, 585-585.	1.4	25
146	Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1185-1191.	2.0	24
147	Effects of Chemotherapy in AIDS-Associated Non-Hodgkin's Lymphoma on Kaposi's Sarcoma Herpesvirus DNA in Blood. <i>Journal of Clinical Oncology</i> , 2009, 27, 2496-2502.	1.6	24
148	Molecular and Clinical Assessment in the Treatment of AIDS Kaposi Sarcoma with Valproic Acid. <i>Clinical Infectious Diseases</i> , 2009, 49, 1946-1949.	5.8	24
149	Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. <i>Leukemia and Lymphoma</i> , 2016, 57, 1731-1734.	1.3	24
150	Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation. <i>Journal of Virology</i> , 2017, 91, .	3.4	23
151	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2020, 4, 5078-5088.	5.2	23
152	Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation. <i>Oncotarget</i> , 2015, 6, 31018-31029.	1.8	23
153	Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 561-567.	2.0	22
154	Epigenetic Silencing of a Proapoptotic Cell Adhesion Molecule, the Immunoglobulin Superfamily Member IGSF4, by Promoter CpG Methylation Protects Hodgkin Lymphoma Cells from Apoptosis. <i>American Journal of Pathology</i> , 2010, 177, 1480-1490.	3.8	22
155	Inter- and Intra-Observer Reliability of Epstein-Barr Virus Detection in Hodgkin Lymphoma using Histochemical Procedures. <i>Leukemia and Lymphoma</i> , 2004, 45, 489-497.	1.3	21
156	Mononucleosis in the Laboratory. <i>Journal of Infectious Diseases</i> , 2005, 192, 1503-1504.	4.0	21
157	A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy. <i>Medical Physics</i> , 2011, 38, 2892-2903.	3.0	21
158	Oral Valacyclovir as Prophylaxis against Herpes Simplex Virus Reactivation During High Dose Chemotherapy for Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 2215-2219.	1.3	20
159	Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1114-1123.	2.5	20
160	Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. <i>Clinical Cancer Research</i> , 2018, 24, 3273-3281.	7.0	20
161	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. <i>Blood Advances</i> , 2019, 3, 2608-2616.	5.2	20
162	Infection and Lymphoma. <i>New England Journal of Medicine</i> , 2003, 349, 1309-1311.	27.0	19

#	ARTICLE	IF	CITATIONS
163	Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2008, 32, 1439-1447.	0.8	18
164	HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths. <i>Molecular Therapy</i> , 2018, 26, 1435-1446.	8.2	18
165	Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. <i>Transplant Infectious Disease</i> , 2021, 23, e13521.	1.7	18
166	Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience. <i>British Journal of Haematology</i> , 2002, 117, 907-913.	2.5	17
167	Dietary Pattern and Risk of Hodgkin Lymphoma in a Population-Based Case-Control Study. <i>American Journal of Epidemiology</i> , 2015, 182, 405-416.	3.4	17
168	Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2075-2081.	2.0	17
169	Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 804083.	2.8	17
170	CpG Methylation as a Tool to Characterize Cell-Free Kaposi Sarcoma Herpesvirus DNA. <i>Journal of Infectious Diseases</i> , 2012, 205, 1095-1099.	4.0	16
171	Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens. <i>Blood</i> , 2000, 95, 241-248.	1.4	16
172	Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2016, 128, 4571-4571.	1.4	15
173	Structural Organization of Human Herpesvirus DNA Molecules. <i>Journal of Investigative Dermatology</i> , 1984, 83, S29-S41.	0.7	14
174	Epstein-Barr virus and bone marrow transplantation. <i>Current Opinion in Oncology</i> , 1995, 7, 102-106.	2.4	14
175	Epstein-Barr virus DNA in body fluids. <i>Current Opinion in Oncology</i> , 2002, 14, 533-537.	2.4	14
176	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1903-1909.	2.0	14
177	R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1261-1265.	1.3	14
178	Haemopoietic cell transplantation in patients living with HIV. <i>Lancet HIV</i> , 2020, 7, e652-e660.	4.7	14
179	Human herpesvirus-8. <i>Current Opinion in Oncology</i> , 1997, 9, 440-449.	2.4	13
180	Conservation of Epstein-Barr Virus Cytotoxic T-Cell Epitopes in Posttransplant Lymphomas. <i>American Journal of Pathology</i> , 2002, 160, 1839-1845.	3.8	13

#	ARTICLE	IF	CITATIONS
181	Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 483-490.	1.3	13
182	Family history of cancer and risk of pediatric and adolescent Hodgkin lymphoma: A Children's Oncology Group study. <i>International Journal of Cancer</i> , 2015, 137, 2163-2174.	5.1	13
183	Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). <i>Clinical Cancer Research</i> , 2016, 22, 328-336.	7.0	13
184	Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 558-565.	7.0	13
185	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). <i>Blood</i> , 2018, 132, 679-679.	1.4	13
186	Serum sCD23 Level in Patients with AIDS-Related Non-Hodgkin's Lymphoma Is Associated with Absence of Epstein-Barr Virus in Tumor Tissue. <i>Clinical Immunology</i> , 1999, 93, 239-244.	3.2	12
187	Hematopoietic stem cell transplantation in HIV-1-infected individuals. <i>Current Opinion in Oncology</i> , 2013, 25, 180-186.	2.4	12
188	Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. <i>Molecular Imaging and Biology</i> , 2017, 19, 429-436.	2.6	12
189	Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial. <i>Blood</i> , 2016, 128, 1346-1346.	1.4	12
190	Blood and marrow transplant for lymphoma patients with HIV/AIDS. <i>Current Opinion in Oncology</i> , 2008, 20, 201-205.	2.4	11
191	Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2016, 57, 666-675.	1.3	11
192	Safety and Preliminary Efficacy of Vorinostat With EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 180-190.e2.	0.4	11
193	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and hematological malignancies: a feasibility study. <i>Lancet HIV</i> , 2020, 7, e602-e610.	4.7	11
194	Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 473-485.	5.2	11
195	Randomized Phase III Trial of 131iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS). <i>Blood</i> , 2011, 118, 661-661.	1.4	11
196	Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 259.e1-259.e11.	1.2	11
197	Plasma cell dyscrasia, Hodgkin lymphoma, HIV, and Kaposi sarcoma-associated herpesvirus. <i>Current Opinion in Oncology</i> , 2002, 14, 543-545.	2.4	9
198	Epstein-Barr virus-related lymphoproliferative disorders. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 249-254.	2.3	9

#	ARTICLE	IF	CITATIONS
199	Immunotherapies for Hodgkin's lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 135-144.	4.4	9
200	Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. <i>Journal of Clinical Virology</i> , 2011, 51, 195-198.	3.1	9
201	Plasma Epstein-Barr Virus DNA for Screening. <i>New England Journal of Medicine</i> , 2017, 377, 584-585.	27.0	9
202	Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. <i>Blood Advances</i> , 2018, 2, 3618-3626.	5.2	9
203	Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production. <i>Journal of Virology</i> , 2019, 93, .	3.4	9
204	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 502-508.	2.0	9
205	Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived. <i>PLoS ONE</i> , 2016, 11, e0163559.	2.5	9
206	Hodgkin Disease/Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 594.	4.9	9
207	Epstein-Barr virus-associated lymphoproliferative disorders. <i>Reviews in Clinical and Experimental Hematology</i> , 2003, 7, 362-74.	0.1	9
208	Posttransplant lymphoproliferative disease: Pathogenesis, monitoring, and therapy. <i>Current Oncology Reports</i> , 2003, 5, 359-363.	4.0	8
209	High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. <i>Leukemia and Lymphoma</i> , 2011, 52, 2076-2081.	1.3	8
210	Clonal immunoglobulin DNA in the plasma of patients with AIDS lymphoma. <i>Blood</i> , 2011, 117, 4860-4862.	1.4	8
211	Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 655-657.	1.3	8
212	Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma. <i>Annals of Hematology</i> , 2014, 93, 1245-1246.	1.8	8
213	Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2306-2310.	2.0	8
214	Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. <i>Haematologica</i> , 2021, 106, 730-735.	3.5	8
215	Greater HLA Disparity Is Associated with Reduced Risk of Relapse and Improved Event-Free Survival after Nonmyeloablative, HLA-Haploidentical BMT with Post-Transplantation High-Dose Cyclophosphamide. <i>Blood</i> , 2008, 112, 150-150.	1.4	8
216	AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 2646-2656.	7.0	8

#	ARTICLE	IF	CITATIONS
217	Viruses as potential targets for therapy in HIV-associated malignancies. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 697-702.	2.2	7
218	CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 1624-1627.	5.2	7
219	Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated Lymphoma. <i>JCO Global Oncology</i> , 2021, 7, 611-621.	1.8	7
220	Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin's Lymphoma: Feasibility and Initial Safety. <i>Blood</i> , 2008, 112, 3059-3059.	1.4	7
221	Biology of the lymphomas. <i>Current Opinion in Oncology</i> , 1991, 3, 806-812.	2.4	6
222	The kiss that scars. <i>Blood</i> , 2006, 108, 8-8.	1.4	6
223	Extended Follow-up of Autologous Bone Marrow Transplantation with 4-Hydroperoxycyclophosphamide (4-HC) Purging for Indolent or Transformed Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 365-373.	2.0	6
224	Kaposi's Sarcoma-Associated Herpesvirus LANA Modulates the Stability of the E3 Ubiquitin Ligase RLIM. <i>Journal of Virology</i> , 2020, 94, .	3.4	6
225	Clonotypic B Cells Circulate in Hodgkin's Lymphoma (HL).. <i>Blood</i> , 2006, 108, 470-470.	1.4	6
226	Post-Transplantation High Dose Cyclophosphamide (Cy) Is Effective Single Agent for Prevention of Acute and Chronic Graft Versus Host Disease after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT). <i>Blood</i> , 2008, 112, 56-56.	1.4	6
227	A Proteomic Platform for EBV and KSHV Serological Screening. <i>Blood</i> , 2010, 116, 1747-1747.	1.4	6
228	Low-Grade Follicular Lymphoma of the Small Intestine: A Challenge for Management. <i>Seminars in Oncology</i> , 2011, 38, 714-720.	2.2	5
229	Arsenicals, the Integrated Stress Response, and Epstein-Barr Virus Lytic Gene Expression. <i>Viruses</i> , 2021, 13, 812.	3.3	5
230	Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085. <i>Blood</i> , 2019, 134, 130-130.	1.4	5
231	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. <i>Blood</i> , 2016, 128, 2992-2992.	1.4	5
232	Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2563-2564.	1.3	4
233	Rarity of Donor-Derived Malignancy after Allogeneic BMT with High-Dose Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S252.	2.0	4
234	Old variables, new value: a refined IPI for DLBCL. <i>Blood</i> , 2014, 123, 800-801.	1.4	4

#	ARTICLE	IF	CITATIONS
235	Prevalence of HIV in Patients with Malignancy and of Malignancy in HIV Patients in a Tertiary Care Center from North India. <i>Current HIV Research</i> , 2019, 16, 315-320.	0.5	4
236	Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study. <i>Clinical Cancer Research</i> , 2021, 27, 4642-4651.	7.0	4
237	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 863.e1-863.e5.	1.2	4
238	Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data. <i>International Journal of Cancer</i> , 1997, 70, 375-382.	5.1	4
239	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 260-269.	0.4	4
240	Nelfinavir Activates Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus Lytic Cycle by Inducing ER Stress. <i>Blood</i> , 2011, 118, 5011-5011.	1.4	4
241	Hiding in plain sight. <i>Blood</i> , 2006, 108, 2891-2891.	1.4	3
242	Imaging Virus-Associated Cancer. <i>Current Pharmaceutical Design</i> , 2008, 14, 3048-3065.	1.9	3
243	Response: Hodgkin lymphoma stem cells. <i>Blood</i> , 2009, 114, 3971-3972.	1.4	3
244	A Human Immunodeficiency Virus Controller With a Large Population of CD4+CD8+ Double-Positive T Cells. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv039.	0.9	3
245	Cytomegalovirus in Adult Allogeneic Blood and Marrow Transplant Patients Before or Around the Period of Neutrophil Recovery: A Single-Center, Retrospective, Descriptive Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa081.	0.9	3
246	A viral protein kinase drug target for tumors?. <i>Journal of Clinical Investigation</i> , 2018, 128, 2197-2198.	8.2	3
247	Allogeneic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients. <i>Blood</i> , 2019, 134, 3342-3342.	1.4	3
248	Encouraging Outcomes In Older Patients (Pts) Following Nonmyeloablative (NMA) Haploidentical Blood or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy). <i>Blood</i> , 2013, 122, 158-158.	1.4	3
249	A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance. <i>Blood</i> , 2019, 134, 778-778.	1.4	3
250	Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disease. <i>Recent Results in Cancer Research</i> , 2021, 217, 197-207.	1.8	3
251	Evaluation of T- and NK-Cell-Targeted Therapies: Is There a Role for Rituximab Prophylaxis?. <i>Clinical Cancer Research</i> , 2009, 15, 2205-2206.	7.0	2
252	High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064). <i>Leukemia and Lymphoma</i> , 2017, 58, 2939-2942.	1.3	2

#	ARTICLE	IF	CITATIONS
253	Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?. <i>Current Oncology Reports</i> , 2019, 21, 65.	4.0	2
254	Transplantation Using Bone Marrow from a (very) HLA Mismatched Unrelated Donor in the Setting of Post-Transplant Cyclophosphamide Is Feasible and Expands Access to Underserved Minorities. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S283-S284.	2.0	2
255	Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2408-2415.	1.3	2
256	Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. <i>Frontiers in Immunology</i> , 2021, 12, 700045.	4.8	2
257	Risk-Adapted Therapy of Aggressive Lymphoma Based on FDG-PET Performed after 2 or 3 Cycles of Initial Chemotherapy. <i>Blood</i> , 2007, 110, 1894-1894.	1.4	2
258	A Pilot Trial of Valproic Acid in Patients with Kaposi's Sarcoma: A Multi-Center Trial of the AIDS Malignancy Consortium. <i>Blood</i> , 2007, 110, 2279-2279.	1.4	2
259	Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus Lytic Cycle Induction with Bortezomib Is a Response to ER Stress. <i>Blood</i> , 2010, 116, 1736-1736.	1.4	2
260	Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy). <i>Blood</i> , 2013, 122, 3407-3407.	1.4	2
261	Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT. <i>Blood</i> , 2015, 126, 2002-2002.	1.4	2
262	AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas. <i>Blood</i> , 2016, 128, 786-786.	1.4	2
263	Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI). <i>Blood</i> , 2014, 124, 680-680.	1.4	2
264	Significance of lymph node fine needle aspiration for the diagnosis of HIV-associated lymphoma in a low-resource setting. <i>Aids</i> , 2022, 36, 1393-1398.	2.2	2
265	AIDS oncology. <i>Current Opinion in Infectious Diseases</i> , 1998, 11, 23-28.	3.1	1
266	EBV, an inhibited receptor kinase, and lymphoma. <i>Blood</i> , 2016, 128, 1542-1543.	1.4	1
267	HIV-Specific T CELLS Expanded from HIV+ and HIV-Naive Donors Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S194-S195.	2.0	1
268	CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid Malignancies. <i>Clinical Chemistry</i> , 2021, 67, 1524-1533.	3.2	1
269	Epstein-Barr virus detection in nasopharyngeal tissues of patients with suspected nasopharyngeal carcinoma. <i>Cancer</i> , 1998, 82, 1449-1453.	4.1	1
270	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). <i>Blood</i> , 2018, 132, 623-623.	1.4	1

#	ARTICLE	IF	CITATIONS
271	Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. <i>Blood</i> , 2019, 134, 4525-4525.	1.4	1
272	A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes. <i>Blood</i> , 2019, 134, 1588-1588.	1.4	1
273	High-Dose Cyclophosphamide (Cy), Rituximab, and a Cancer Vaccine for Relapsed Classical Hodgkin's Lymphoma (cHL). <i>Blood</i> , 2010, 116, 3954-3954.	1.4	1
274	Outcomes Of Nonmyeloablative (NMA) Haploidentical Blood Or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy) For Lymphoma. <i>Blood</i> , 2013, 122, 2091-2091.	1.4	1
275	Lymphoproliferative Disease Risk in Patients with Autoimmune Disease: Clustering of Primary CNS Lymphoma with Drug Regimen and Disease Process. <i>Blood</i> , 2015, 126, 1490-1490.	1.4	1
276	Plasma viral DNA as a marker of tumor response in EBV(+) Hodgkin lymphoma in a phase III study (E2496).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8003-8003.	1.6	1
277	A phase IB trial of 5-azacitidine (5AC) and suberoylanilide hydroxamic acid (SAHA) in patients with metastatic or locally recurrent nasopharyngeal carcinoma (NPC) and NK-T cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e17017-e17017.	1.6	1
278	AMC075: A randomized phase II trial of vorinostat with R-EPOCH in aggressive HIV-related NHL.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7573-7573.	1.6	1
279	Unveiling kaposi sarcoma viral antigens. <i>Oncotarget</i> , 2017, 8, 50325-50326.	1.8	1
280	Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma.. <i>Blood</i> , 2004, 104, 901-901.	1.4	1
281	A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8602-TPS8602.	1.6	1
282	Rebound HIV viremia with meningoencephalitis following antiretroviral therapy interruption after allogeneic bone marrow transplant. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	2.1	1
283	Recent experimental studies in lymphoma. <i>Current Opinion in Oncology</i> , 1990, 2, 811-815.	2.4	0
284	Cancer in AIDS. <i>Current Opinion in Oncology</i> , 1995, 7, 427-428.	2.4	0
285	AIDS oncology emerges as a clinical discipline. <i>Current Opinion in Oncology</i> , 1996, 8, 371-372.	2.4	0
286	New controversies and new directions. <i>Current Opinion in Oncology</i> , 2000, 12, 435-437.	2.4	0
287	Virus as master of the house. <i>Blood</i> , 2003, 102, 3861-3862.	1.4	0
288	Hodgkin twins: double good, double trouble. <i>Blood</i> , 2008, 111, 3310-3310.	1.4	0

#	ARTICLE	IF	CITATIONS
289	When differentiation goes viral. <i>Blood</i> , 2011, 117, 5790-5791.	1.4	0
290	Using CpG Methylation to Monitor Ebv in Plasma. <i>Annals of Oncology</i> , 2014, 25, v24.	1.2	0
291	763. HIV-Specific T Cells Can Be Expanded from Virus-Naive Donors to Target a Range of Viral Epitopes: Implications for a Cure Strategy After Allogeneic HSCT. <i>Molecular Therapy</i> , 2016, 24, S302.	8.2	0
292	The Use of Post-Transplantation Cyclophosphamide after Myeloablative, HLA-Matched Allogeneic Bone Marrow Transplantation Minimizes the Need for Additional Immunosuppression. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S46-S47.	2.0	0
293	Resistance Is Futile: Engineering the Adoptive T-Cell Therapies of the Future. <i>Journal of Clinical Oncology</i> , 2018, 36, 1140-1142.	1.6	0
294	Aberrant Hedgehog Signaling Represents a Novel Therapeutic Target in B Cell Lymphomas.. <i>Blood</i> , 2007, 110, 3582-3582.	1.4	0
295	Clonal Heavy and Light Chain Immunoglobulin DNA in Plasma/Serum of AIDS Lymphoma Patients.. <i>Blood</i> , 2007, 110, 1579-1579.	1.4	0
296	Efficacy of a Brief, Cyclophosphamide-Intensive Regimen for Older Patients with Newly Diagnosed Burkitt's or Atypical Burkitt's Lymphoma/Leukemia.. <i>Blood</i> , 2009, 114, 2685-2685.	1.4	0
297	Clonal Ig DNA Detection In Plasma From Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2010, 116, 3127-3127.	1.4	0
298	Cell-free EBV DNA in Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7-7.	1.6	0
299	Nonmyeloablative Allogeneic (Allo) BMT for B-Cell Lymphoma with Posttransplant Rituximab: Donor Selection by Prioritizing FCGR3A-158 Polymorphism Over HLA Matching.. <i>Blood</i> , 2012, 120, 3107-3107.	1.4	0
300	Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.. <i>Blood</i> , 2012, 120, 3084-3084.	1.4	0
301	Incidence of posttransplantation lymphoproliferative disorder (PTLD) following allogeneic blood or marrow transplantation (alloBMT) using post-transplantation cyclophosphamide (PT-Cy) for graft-versus-host disease (GVHD) prophylaxis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7009-7009.	1.6	0
302	Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma. <i>Blood</i> , 2013, 122, 4232-4232.	1.4	0
303	Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients. <i>Blood</i> , 2013, 122, 1785-1785.	1.4	0
304	A Rise in CNS Lymphoproliferative Disease Incidence Reveals a Protective Role of Calcineurin Inhibitors. <i>Blood</i> , 2014, 124, 3020-3020.	1.4	0
305	AMC075: The Combination of Vorinostat with Chemotherapy and Rituximab Is Tolerable and Feasible in HIV-Related B-Cell Non-Hodgkin's Lymphoma with High-Risk Features. <i>Blood</i> , 2014, 124, 4473-4473.	1.4	0
306	High Frequency of Identical Lymphoma Clones Detected in Pre-Treatment Tumor and Plasma from Untreated Patients with HIV-Associated Lymphomas: Prospective Multicenter Trial of the AIDS Malignancy Consortium (AMC 064). <i>Blood</i> , 2014, 124, 1680-1680.	1.4	0

#	ARTICLE	IF	CITATIONS
307	Clonal Hematopoiesis Is More Common in People Living with HIV and May be Associated with Increased Prevalence of Cardiovascular Disease. <i>Blood</i> , 2021, 138, 4298-4298.	1.4	0
308	Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab. <i>Blood</i> , 2021, 138, 1846-1846.	1.4	0
309	Epstein-Barr Virus Infection. , 0, , 1410-1418.		0